<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04468334</url>
  </required_header>
  <id_info>
    <org_study_id>RS-011, Appendix 16</org_study_id>
    <nct_id>NCT04468334</nct_id>
  </id_info>
  <brief_title>aMAZE Trial Continued Access Protocol</brief_title>
  <acronym>aMAZE CAP</acronym>
  <official_title>Non-randomized, Multicenter Expanded Use Evaluation of the LARIAT® Suture Delivery Device (Appendix 16 to Ongoing Investigation)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>AtriCure, Inc.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>AtriCure, Inc.</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>Yes</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      aMAZE CAP is an extension to the current aMAZE Trial investigation
      (IDEG150107/NCT02517397/Protocol Appendix 16) in the form of a nested, non-randomized
      registry, to allow ongoing treatment of subjects and the collection of additional safety and
      effectiveness data at existing aMAZE investigational sites.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      For consistency, aMAZE CAP primary and secondary safety and efficacy endpoints, eligibility
      criteria and follow up visit assessments remain unchanged from the current aMAZE Trial
      investigation (NCT02517397).
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">January 2, 2020</start_date>
  <completion_date type="Anticipated">January 2023</completion_date>
  <primary_completion_date type="Anticipated">December 2022</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Freedom from episodes of atrial fibrillation &gt; 30 seconds at 12 months post index pulmonary vein isolation</measure>
    <time_frame>12 months following Pulmonary Vein Isolation catheter ablation procedure</time_frame>
    <description>Measured by 24-hour Holter Monitoring</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Freedom from any atrial fibrillation/atrial tachycardia/atrial flutter recurrence defined as any episode &gt; 30 seconds with or without AAD</measure>
    <time_frame>Following the 90 day blanking period through 12 months post-index pulmonary vein isolation</time_frame>
    <description>Measured by 24-hour Holter Monitoring</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Composite endpoint of stroke of any cause and systemic embolism as adjudicated by the clinical events committee</measure>
    <time_frame>12 months following index pulmonary vein isolation</time_frame>
  </secondary_outcome>
  <other_outcome>
    <measure>LARIAT Technical Success</measure>
    <time_frame>Immediately post-LARIAT ligation (acute) and at 12 months following index pulmonary vein isolation</time_frame>
    <description>Successful placement of the LARIAT device pre-tied suture around the left atrial appendage to achieve left atrial appendage ligation defined as ≤1 ± 1mm diameter residual communication w/ left atrium, as assessed by transesophageal echocardiography</description>
  </other_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">85</enrollment>
  <condition>Atrial Fibrillation</condition>
  <arm_group>
    <arm_group_label>LARIAT + PVI Treatment Group</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Percutaneously isolate and ligate the Left Atrial Appendage (LAA) from the left atrium (LA) with the LARIAT System prior to planned pulmonary vein isolation (PVI) catheter ablation
Subgroup 1: Radiofrequency (RF) PVI catheter ablation treatment (n&lt;65) Subgroup 2: Cryoballoon PVI catheter ablation treatment (n&lt;20)</description>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>LARIAT + PVI</intervention_name>
    <description>LAA ligation with the LARIAT System initially performed followed by adjunctive PVI catheter ablation (RF or cryoballoon) in staged procedures</description>
    <arm_group_label>LARIAT + PVI Treatment Group</arm_group_label>
    <other_name>LAA + RF PVI</other_name>
    <other_name>LAA + Cryo PVI</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Documented diagnosis of symptomatic continuous persistent or longstanding persistent
             non-valvular atrial fibrillation

          -  Failed at least one Class I or III Antiarrythmic drug (AAD) and therefore, eligible
             and intended for standard of care catheter ablation;

          -  Life expectancy ≥ 1 year;

          -  Willing and able to return to and comply with scheduled follow-up visits and tests;
             and

          -  Willing and able to provide written informed consent

        Exclusion Criteria:

          -  Prior procedure involving opening of the pericardium or entering the pericardial space
             (e.g., coronary artery bypass graft, heart transplantation, valve surgery) where
             adhesions are suspected;

          -  Any prior epicardial ablation or any type of left-sided atrial ablation procedure;

          -  LA diameter &gt; 6 cm as measured by computerized tomography and confirmed by the imaging
             core laboratory;

          -  Documented embolic stroke, transient ischemic attach or suspected neurologic event
             within 3 months prior to the planned study intervention;

          -  Currently exhibits New York Heart Association Class IV heart failure symptoms;

          -  Documented history of right heart failure specifically when right ventricle exceeds
             the left ventricular size;

          -  Documented history of myocardial infarction (MI) within 3 months prior to the planned
             study intervention;

          -  Documented history of unstable angina within 3 months prior to the planned study
             intervention;

          -  Documented history of cardiogenic shock, hemodynamic instability or any medical
             condition in which intra-aortic balloon pump (IABP) therapy is clinically indicated
             within 3 months prior to the planned study intervention;

          -  Documented symptomatic carotid disease, defined as &gt; 70% stenosis or &gt; 50% stenosis
             with symptoms;

          -  Diagnosed active local or systemic infection, septicemia or fever of unknown origin at
             tme of baseline screening;

          -  Chronic renal insufficiency defined as eGFR &lt; 30 mL/min/1.73m2 withing 3 months prior
             to planned study intervention;

          -  End Stage Renal Disease (ESRD) or documented history of renal replacement / dialysis;

          -  Current documented history of clinically significant liver disease which predisposes
             the subject to significant bleeding risk (clinically defined by the treating
             physician);

          -  Any history of thoracic radiation with the exception of localized radiation treatment
             for breast cancer;

          -  Current documented use of long-term treatment with oral corticoid steroids, not
             including use of inhaled steroids for respiratory diseases;

          -  Active pericarditis;

          -  Active endocarditis;

          -  Any documented history or autoimmune disease associated with pericarditis;

          -  Evidence of Pectus Excavatum (documented and clinically defined by the treating
             physician);

          -  Untreated severe scoliosis (documented and clinically defined by treating physician);

          -  Documented Left Ventricular Ejection Fraction (LVEF) &lt; 30% within 30 days prior to
             planned intervention;

          -  Documented presence of implanted congenital defect closure devices, (e.g., atrial
             septal defect, patent foramen ovale or ventricular septal defect device);

          -  Previously attempted occlusion of the left atrial appendage (by any surgical or
             percutaneous method);

          -  Inability, or unwillingness or contraindication to undergo TEE or CTA imaging or
             24-hour Holter monitoring;

          -  Body Mass Index (BMI) &gt; 40;

          -  Evidence of active Graves disease;

          -  Current untreated hypothyroidism;

          -  Any contraindication to suture, endovascular device, or other minimally invasive
             techniques including percutaneous, transseptal, and/or sub-xiphoid access;

          -  Subject is pregnant or plans / desires to get pregnant within next 12 months;

          -  Current enrollment in an investigation or study of an investigational device or
             investigational drug that would interfere with this study and the required follow up;

          -  Mental impairment or other psychiatric conditions which may not allow patient to
             understand the nature, significance and scope of the study;

          -  Any other criteria, medical illness or comorbidity which would make the subject
             unsuitable to participate in this study as determined by the clinical site Primary
             Investigator;

        Additional Exclusion Criteria: Based on Screening / Pre-procedure Imaging

        Subjects will also be excluded if they meet any of the following:

        Based on screening computed tomography angiography performed within 90 days prior to study
        intervention as confirmed by the core lab:

        Left atrial appendage morphology: Superior-posterior oriented left atrial appendage (i.e.
        superior C shape), that has Left atrial appendage distal apex extending posterior to the
        ostium of the appendage.

        Left atrial appendage positioned behind the pulmonary artery; or All other left atrial
        morphology: Left atrial appendage LARIAT approach width &gt; 50 mm.

        Based on a peri-procedural imaging (transesophageal echocardiography) at time of LARIAT or
        catheter ablation) and confirmed by institution's designated LARIAT echocardiographer:

        Intracardiac thrombus; or Significant mitral valve stenosis (i.e., mitral valve stenosis &lt;
        1.5cm2)

        NOTE: It is anticipated that a majority of subjects enrolled in the aMAZE CAP Trial will be
        elderly US Medicare beneficiaries. Therefore, the results from the aMAZE CAP Trial are
        expected to be generalizable to the Medicare population
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>80 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>David J Wilber, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Loyola University Department of Medicine</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Dhanunjaya Lakkireddy, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Kansas City Cardiac Arrhythmia Research</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Pamelia P Simons, BS, RT</last_name>
    <phone>612-240-1100</phone>
    <email>psimons@atricure.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>Stanford University</name>
      <address>
        <city>Stanford</city>
        <state>California</state>
        <zip>94305</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Sarah Daadi</last_name>
      <phone>650-498-5590</phone>
      <email>sedaadi@stanford.edu</email>
    </contact>
    <investigator>
      <last_name>Nitish Badhwar, M.D.</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>St. Vincent's HealthCare</name>
      <address>
        <city>Jacksonville</city>
        <state>Florida</state>
        <zip>32204</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Lisa Joseph</last_name>
      <phone>904-308-6405</phone>
      <email>lisa.joseph@ascension.org</email>
    </contact>
    <investigator>
      <last_name>Saumil Oza, M.D.</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Northwestern University / Bluhm Cardiovascular Institute</name>
      <address>
        <city>Chicago</city>
        <state>Illinois</state>
        <zip>60611</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Amy Carswell</last_name>
      <phone>312-926-7554</phone>
      <email>Amy.carswell@nm.org</email>
    </contact>
    <investigator>
      <last_name>Albert C. Lin, M.D.</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Loyola University Center for Heart and Vascular Medicine</name>
      <address>
        <city>Maywood</city>
        <state>Illinois</state>
        <zip>60153</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Nancy Schoenecker</last_name>
      <phone>708-216-2646</phone>
      <email>nschoenecker@luc.edu</email>
    </contact>
    <investigator>
      <last_name>David Wilber, M.D.</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Prairie Education and Research Cooperative</name>
      <address>
        <city>Springfield</city>
        <state>Illinois</state>
        <zip>62769</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Katie Mottershaw</last_name>
      <phone>217-492-9100</phone>
      <phone_ext>114</phone_ext>
      <email>kmottershaw@prairieresearch.com</email>
    </contact>
    <investigator>
      <last_name>Ziad Issa, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Community Hospital</name>
      <address>
        <city>Munster</city>
        <state>Indiana</state>
        <zip>46321</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Tera Gagne</last_name>
      <phone>219-703-1152</phone>
      <email>Tera.M.Gagne@comhs.org</email>
    </contact>
    <investigator>
      <last_name>William Spear, M.D.</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Iowa Heart Center</name>
      <address>
        <city>West Des Moines</city>
        <state>Iowa</state>
        <zip>50266</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Sara Burg</last_name>
      <phone>515-633-3845</phone>
      <email>scburg@iowaheart.com</email>
    </contact>
    <investigator>
      <last_name>Troy Hounshell, D.O.</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Kansas City Cardiac Arrthymia Research</name>
      <address>
        <city>Overland Park</city>
        <state>Kansas</state>
        <zip>66215</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Donita Atkins</last_name>
      <phone>816-651-1969</phone>
      <email>donita.atkins@hcahealthcare.com</email>
    </contact>
    <investigator>
      <last_name>Dhanunjaya Lakkireddy, M.D.</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Cardiovascular Institute of the South Clinical Research Corporation</name>
      <address>
        <city>Houma</city>
        <state>Louisiana</state>
        <zip>70360</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Deanna Benoit</last_name>
      <phone>985-873-5613</phone>
      <email>Deanna.Benoit@cardio.com</email>
    </contact>
    <contact_backup>
      <last_name>Vickie Parfait</last_name>
      <phone>985-873-5603</phone>
      <email>Vicky.Parfait@cardio.com</email>
    </contact_backup>
    <investigator>
      <last_name>Peter Fail, M.D.</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Johns Hopkins</name>
      <address>
        <city>Baltimore</city>
        <state>Maryland</state>
        <zip>21287</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Michele Martucci</last_name>
      <phone>410-502-0517</phone>
      <email>mmill148@jhmi.edu</email>
    </contact>
    <investigator>
      <last_name>Ronald Berger, M.D.</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>UP Health System- Marquette</name>
      <address>
        <city>Marquette</city>
        <state>Michigan</state>
        <zip>49855</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Heather Arpiainen</last_name>
      <phone>906-225-4733</phone>
      <email>Heather.Arpiainen@mghs.org</email>
    </contact>
    <investigator>
      <last_name>Rudolph Evonich, III, M.D.</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>The Valley Hospital</name>
      <address>
        <city>Ridgewood</city>
        <state>New Jersey</state>
        <zip>07450</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Kimberly Michel</last_name>
      <phone>201-447-8453</phone>
      <email>kmichel@valleyhealth.com</email>
    </contact>
    <investigator>
      <last_name>Daniel Musat, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Suneet Mittal, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>New Mexico Heart Institute</name>
      <address>
        <city>Albuquerque</city>
        <state>New Mexico</state>
        <zip>87102</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Deanna Garcia</last_name>
      <phone>505-843-2804</phone>
      <email>deannag@nmhi.com</email>
    </contact>
    <investigator>
      <last_name>Michael Bestawros, M.D.</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>New York University Langone Medical Center</name>
      <address>
        <city>New York</city>
        <state>New York</state>
        <zip>10016</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>April Jacobs</last_name>
      <phone>212-263-7704</phone>
      <email>April.Jacob@nyulangone.org</email>
    </contact>
    <investigator>
      <last_name>Anthony Aizer, M.D.</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Southern Oregon Cardiology</name>
      <address>
        <city>Medford</city>
        <state>Oregon</state>
        <zip>97504</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Jean Anne Eisenhaure</last_name>
      <phone>541-930-7253</phone>
      <email>eisenhaurej@socardiology.com</email>
    </contact>
    <investigator>
      <last_name>Eric Pena, M.D.</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Trident Medical Center</name>
      <address>
        <city>Charleston</city>
        <state>South Carolina</state>
        <zip>29406</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Valerie Pistillo</last_name>
      <phone>843-847-5025</phone>
      <email>Valerie.Pistillo@HCAhealthcare.com</email>
    </contact>
    <investigator>
      <last_name>Frank Cuoco, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Texas Cardiac Arrhythmia Research Foundation</name>
      <address>
        <city>Austin</city>
        <state>Texas</state>
        <zip>78705</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Deb Cardinal, RN</last_name>
      <phone>512-431-4868</phone>
      <email>dscardinal@austinheartbeat.com</email>
    </contact>
    <investigator>
      <last_name>Rodney Horton, M.D.</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Baylor - St. Luke's Medical Center</name>
      <address>
        <city>Houston</city>
        <state>Texas</state>
        <zip>77030</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Aline Barzilla, CCRC</last_name>
      <phone>713-798-1037</phone>
      <email>barzilla@bcm.edu</email>
    </contact>
    <investigator>
      <last_name>Abdi Rasekh, MD, FACC</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Houston Methodist</name>
      <address>
        <city>Houston</city>
        <state>Texas</state>
        <zip>77030</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Maria Del Pino</last_name>
      <phone>346-238-0290</phone>
      <email>mdelpino@houstonmethodist.org</email>
    </contact>
    <investigator>
      <last_name>Miguel Valderrabano, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Christus Trinity Mother Frances Health System</name>
      <address>
        <city>Tyler</city>
        <state>Texas</state>
        <zip>75701</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Carol Cushman</last_name>
      <phone>903-606-8846</phone>
      <email>Carol.Cushman@CHRISTUShealth.org</email>
    </contact>
    <investigator>
      <last_name>Stanislav Weiner, M.D.</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <reference>
    <citation>Lee RJ, Lakkireddy D, Mittal S, Ellis C, Connor JT, Saville BR, Wilber D. Percutaneous alternative to the Maze procedure for the treatment of persistent or long-standing persistent atrial fibrillation (aMAZE trial): Rationale and design. Am Heart J. 2015 Dec;170(6):1184-94. doi: 10.1016/j.ahj.2015.09.019. Epub 2015 Oct 3.</citation>
    <PMID>26678640</PMID>
  </reference>
  <verification_date>June 2020</verification_date>
  <study_first_submitted>July 8, 2020</study_first_submitted>
  <study_first_submitted_qc>July 10, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">July 13, 2020</study_first_posted>
  <last_update_submitted>July 10, 2020</last_update_submitted>
  <last_update_submitted_qc>July 10, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">July 13, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Left Atrial Appendage</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Atrial Fibrillation</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

